Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.
Anteris Technologies Ltd is an Australia-based structural heart company engaged in the sale, distribution, maintenance and implementation of infusion solutions to hospitals and health facilities. It is also involved in the manufacturing, sale and distribution of proprietary ADAPT regenerative tissue products globally; and research and development of regenerative medicine and immunotherapies. Its operating segments are Infusion business; ADAPT business; and Regenerative medicine R&D, of which it derives key revenue from the ADAPT business covering bio implant operations; inclusive of sales, distribution and manufacturing. The company derives key revenue from Australia and the U.S.
Toowong, QLD, 4066, Australia